Element Biosciences has announced an upsized Series E financing round designed to accelerate the commercialization of its expanding ecosystem of genomic and multiomic research solutions. This funding, which includes a $175 million investment from longstanding investor Samsung Electronics and additional undisclosed contributions from other investors, is intended to expand the company's global presence and advance its product roadmap across research, translational science, and diagnostic applications. The investment aims to make critical biological insights more accessible to scientists worldwide while strengthening the company's position in the medtech and life sciences sectors.
Element Biosciences Series E Funding and Samsung Investment
The upsized Series E round features a $175 million investment from Samsung Electronics, following a $277 million Series D round announced in July 2024. This new capital, which remains subject to regulatory approval, is intended to support the adoption of Element's current portfolio and the development of future innovations. TM Roh, President and Head of the Device eXperience (DX) Division at Samsung Electronics, noted that the investment reflects Samsung's belief in the broad adoption of sequencing as a foundational pillar of precision medicine. Samsung's continued investment in life sciences and precision medicine is aimed at the ultimate goal of enhancing overall human health outcomes.
VITARI, AVITI24, and AVITI Dx Product Roadmap
The new financing will support the commercialization and adoption of a diverse portfolio of genomic and multiomic technologies. This includes the AVITI system and the recently announced VITARI, a high-throughput benchtop system. Furthermore, the funding will facilitate the forthcoming launches of AVITI Dx and the introduction of tissue profiling on the AVITI24 platform. These technologies are positioned to enable researchers to generate richer biological insights through integrated genomic, transcriptomic, protein, spatial, and cellular analyses, bridging the gap between foundational research and clinical applications in personalized diagnostics.
Global Expansion and Open Architecture Strategy
Since the initial launch of AVITI in 2022, Element has expanded its global customer footprint to more than 40 countries, serving a wide array of academic, pharmaceutical, biotechnology, and clinical research organizations. A key component of the company's strategy is the strengthening of an open, interoperable architecture. This design is specifically intended to allow technology, pharmaceutical, and scientific partners to develop and scale their own proprietary applications directly on Element platforms, fostering a collaborative ecosystem for scientific discovery.
Key Takeaways
- Samsung Electronics invested $175 million as part of an upsized Series E round, following a $277 million Series D round in July 2024.
- The funding supports the commercialization of the VITARI high-throughput system and the upcoming launches of AVITI Dx and tissue profiling on AVITI24.
- Element Biosciences has expanded its global reach to over 40 countries across clinical, biotech, and academic sectors.
TechInsyte's Take
The strategic investment from Samsung Electronics signals a push toward integrating sequencing as a foundational pillar of precision medicine. For infrastructure and SaaS buyers in the life sciences space, the focus on an open, interoperable architecture suggests a shift toward platform-based ecosystems rather than closed proprietary systems. Executives should monitor the regulatory approval of this funding and the subsequent launch timelines for the AVITI Dx and AVITI24 updates.
Source: Businesswire
